Applied genetic technologies corporation.
AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies with the potential to ...
--Applied Genetic Technologies Corporation, a biotechnology company conducting human clinical trials of adeno-associated virus- based gene therapies for the treatment of rare diseases, today ...Dec 12, 2018 · Applied Genetic Technologies Corporation announced that Biogen has terminated collaboration agreement effective as of March 8, 2019. Upon termination, the company will regain commercial rights to the... Applied Genetic Technologies Corporation . 14193 NW 119 th Terrace, Suite 10 . Alachua, Florida 32615 (386) 462-2204 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications . on Behalf of the Person(s) Filing Statement) With copies to: Stacie S. Aarestad :It has been a tough year for gene therapy companies, and the latest player to accept reality is Applied Genetic Technologies Corporation, which today succumbed to a lowball bid from the investment company Syncona. It is clear to see why AGTC, running short of cash and with a flatlining share price, felt compelled to accept the offer.
GAINESVILLE, Fla., and CAMBRIDGE, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (“AGTC” or the “Company”) (Nasdaq: AGTC), a clinical-stage biotechnology ...
GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 04, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno ...It has been a tough year for gene therapy companies, and the latest player to accept reality is Applied Genetic Technologies Corporation, which today succumbed to a lowball bid from the investment company Syncona. It is clear to see why AGTC, running short of cash and with a flatlining share price, felt compelled to accept the offer.
AGTC presentations at ARVO 2022: Findings on Visual Photosensitivity in Two Phase 1/2 Clinical Trials of Subretinal Gene Therapy with AGTC-401 and AGTC-402 for CNGB3 and CNGA3 ACHM (paper ...D.R.K., G.Y., and J.D.C. are employees of and hold share options in Applied Genetic Technologies Corporation, and have a conflict of interest to the extent that this work potentially increases their personal financial interests. J.M.W. is a consultant to ReGenX Holdings, and is a founder of, ...A high-level overview of Applied Genetic Technologies Corporation (AGTC) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.Applied Genetic Technologies Corp: ClinicalTrials.gov Identifier: NCT02416622 Other Study ID Numbers: AGTC-RS1-001 : First Posted: April 15, 2015 Key Record Dates: Results First Posted: July 1, 2020: Last Update Posted: June 12, 2023 Last Verified: June 2023
AGTC and Otonomy each disclaim any obligation to update any forward-looking statements, except as required by law. AGTC Contacts: IR/PR Contacts: David Carey (IR) or Tom Vickery (PR) Lazar ...
Are you tired of the hassle that comes with filing your tax refund application through traditional means? Luckily, with advancements in technology, you can now apply for a tax refund online.
Applied Genetic Technologies Corporation June 24, 2021 at 7:00 AM · 6 min read - Activities to support the next stage of clinical development of ACHM B3 candidate are ongoing-Dec 1, 2022 · GAINESVILLE, Fla. and CAMBRIDGE, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (“AGTC” or the “Company”) (Nasdaq: AGTC), announced today the successful ... Track Applied Genetic Technologies Corp (AGTC) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsGAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), President and Chief Executive Officer, Sue Washer, sent the ...Applied Genetic Technologies is not a large company by global standards. It has a market capitalization of US$122m, which means it wouldn't have the attention of many institutional investors.Applied Genetic Technologies Corporation October 23, 2022 at 7:05 PM · 10 min read Upfront consideration in cash of $0.34 per share representing a premium of approximately 42% over AGTC’s ...Applied Genetic Technologies Corporation (AGTC) is developing a recombinant adeno-associated virus (rAAV) vector AGTC-501, also designated rAAV2tYF-GRK1-hRPGRco, to treat X-linked retinitis pigmentosa (XLRP) in patients with mutations in the retinitis pigmentosa GTPase regulator (RPGR) gene.
OTO-825 is the clinical candidate targeting the gap junction beta-2 (GJB2) gene developed under the company’s collaboration with Applied Genetic Technologies Corporation (Nasdaq: AGTC).Nov 28, 2023 · Applied Genetic Technologies Co. (NASDAQ:AGTC) released its quarterly earnings data on Tuesday, November, 9th. The biotechnology company reported ($0.40) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by $0.05. During the same quarter last year, the firm posted ($0.60) earnings per share. Dec 1, 2022 · Introductory Note As previously disclosed on a Form 8-K filed with the Securities and Exchange Commission ("SEC") on October 24, 2022, Applied Genetics Technology Corporation, a Delaware corporation (the "Company "), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Alliance Holdco Limited, a private limited company organized under the laws of England and Wales (the ... GAINESVILLE, Fla. and CAMBRIDGE, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (“AGTC” or the …Applied Genetic Technologies Co. (NASDAQ:AGTC) released its quarterly earnings results on Tuesday, November, 9th. The biotechnology company reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.35) by $0.05. During the same period in the prior year, the business earned ($0.60) earnings …Alliance Acquisition Sub, Inc., a Delaware corporation (“Purchaser”), is offering to purchase (the “Offer”) all outstanding shares of common stock, par value $0.001 per share (the “Shares”), of Applied Genetic Technologies Corporation, a Delaware corporation (the “Company”), at a price per Share of $0.34, to the holder in cash, without interest and less any applicable ...
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (“AGTC” or the “Company”) (Nasdaq: AGTC), announced today the successful ...
Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company uses gene therapy platform to develop genetic …Applied Genetic Technologies Corporation (NASDAQ: NASDAQ:AGTC) is a clinical-stage biotechnology company developing genetic therapies for rare and …Applied Genetic Technologies Corporation (AGTC) is developing a recombinant adeno-associated virus (rAAV) vector AGTC-501, also designated rAAV2tYF-GRK1-hRPGRco, to treat X-linked retinitis pigmentosa (XLRP) in patients with mutations in the retinitis pigmentosa GTPase regulator (RPGR) gene.The vector contains a codon-optimized …Applied Genetic Technologies Corporation Contacts: IR Contact: David Carey Lazar FINN Partners T: (212) 867-1768 [email protected] Corporate Contact: Jonathan Lieber Chief Financial Officer Applied Genetic Technologies Corporation T: (617) 843-5778 ...Nov 27, 2023 · Applied Genetic Technologies Corporation (AGTC) reported positive 3-month interim data from its ongoing phase 2 Skyline trial of AGTC-501, a recombinant AAV viral vector-based gene therapy targeting mutations in the RPGR gene in patients with X-linked retinitis pigmentosa (XLRP). Oct 24, 2022 · GAINESVILLE, Fla. and CAMBRIDGE, Mass., Oct. 23, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical-stage biotechnology company focused on the... GAINESVILLE, Florida and CAMBRIDGE, Massachusetts, October 23, 2022 – Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical-stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on ...Jun 6, 2022 · GAINESVILLE, Fla., and CAMBRIDGE, Mass., June 06, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical-stage biotechnology company focused on the ...
October 24, 2022. Venture firm Syncona is acquiring Applied Genetic Technologies Corporation, a company focused on the development and commercialization of adeno-associated virus-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases, for approximately $23.5 million plus ...
Applied Genetic Technologies Company Info. Applied Genetics Technologies Corporation (AGTC) is developing therapies designed to transform the lives of patients with severe diseases, offering hope ...
Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company uses gene therapy platform to develop genetic therapies for patients suffering from rare and debilitating diseases.Oct 24, 2022 · These now include Applied Genetic Technologies Corp., which, rather than face the “challenging” funding environment ahead, has opted for a $23.5 million sale to investment fund Syncona. AGTC ... Applied Genetic Technologies Corporation (AGTC) reported positive 3-month interim data from its ongoing phase 2 Skyline trial of AGTC-501, a recombinant …Dec 12, 2018 · Applied Genetic Technologies Corporation announced that Biogen has terminated collaboration agreement effective as of March 8, 2019. Upon termination, the company will regain commercial rights to the... Conference Call and Webcast. Syncona and AGTC will host a conference call and webcast to review the details of the transaction on October 24, 2022 at 7:30 a.m. ET. To access the call, dial 877-407-6184 (U.S. participants) or 201-389-0877 (non-U.S. participants). A live webcast will be available in the Events and Presentations section of …In today’s digital age, the entertainment industry has embraced technology to make it easier for aspiring actors to showcase their talent. One of the most convenient ways to apply for acting auditions is through online platforms.GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), President and Chief Executive Officer, Sue Washer, sent the ...GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (“AGTC” or the “Company”) (Nasdaq: AGTC), announced today that a ...GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a …Exhibit (a)(25) Applied Genetic Technologies Corporation Urges Shareholders to Tender Their Shares by November 28, 2022 . GAINESVILLE, Florida and CAMBRIDGE, Massachusetts, November 14, 2022 – Applied Genetic Technologies Corporation (Nasdaq: AGTC), President and Chief Executive Officer, Sue Washer, sent the following …Feb 4, 2021 · Applied Genetic Technologies Corporation T: (617) 843-5728 [email protected]. Stephen Potter Chief Business Officer Applied Genetic Technologies Corporation T: (617) 413-2754
Purpose: To evaluate the safety and efficacy of rAAV2tYF-CB-hRS1, a recombinant adeno-associated virus vector expressing retinoschisin (RS1), in individuals with retinal disease caused by mutations in the RS1 gene. Design: Open-label, phase I or II dose-escalation clinical trial. Subjects: Twenty-two adults and 5 children with X-linked retinoschisis …A newly established portfolio company of Syncona Limited will commence a tender offer to acquire all outstanding shares of AGTC for $0.34 per share, valuing AGTC at approximately $23.5 million (£20.8 million [1] ), plus the potential for up to an additional $50.0 million (up to $0.73 per share) in contingent value rights in the event certain ...Applied Genetic Technologies Corporation Contacts: IR Contact: David Carey Lazar FINN Partners T: (212) 867-1768 [email protected]. Corporate Contact: Jonathan Lieber Chief Financial ...Oct 24, 2022 · GAINESVILLE, Fla. and CAMBRIDGE, Mass., Oct. 23, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical-stage biotechnology company focused on the... Instagram:https://instagram. 1921 silver dollar pricehow to buy mortgage backed securitieshigh end watch insurancet futures Applied Genetic Technologies Corporation, a Cambridge- and Florida-based gene therapy firm better known as AGTC could go private through an acquisition by a Floridian investment firm. duke ennergybest budget desk In today’s digital age, businesses of all sizes are increasingly relying on technology to conduct their operations. With the rise of remote work and the growing number of devices connected to corporate networks, ensuring the security of end... webull level 2 options Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company uses gene therapy platform to develop genetic therapies for patients suffering from rare and debilitating diseases. Its focus is on the field of ophthalmology where it has active clinical programs in X-linked retinitis pigmentosa (XLRP ...Applied Genetic Technologies Corporation (AGTC) is developing a recombinant adeno-associated virus (rAAV) vector AGTC-501, also designated AAV2tYF-GRK1-RPGRco, to treat retinitis pigmentosa (RP) in patients with mutations in the retinitis pigmentosa GTPase regulator (RPGR) gene.APPLIED GENETIC TECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware : 001-36370 : 59-3553710 (State or other jurisdiction. of incorporation) (Commission. File Number) (IRS Employer. Identification Number) 14193 NW 119 th Terrace . Suite 10 . Alachua, Florida, 32165